NCT06841731
A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial completed
- Study completion date changed from estimate of Oct 2026 to Oct 9, 2026
Notable Primary completion date changed from estimate of Feb 2026 to Sep 22, 2026 Show 7 more changesShow less
- Eligibility criteria expanded, about 18 words
- Enrollment closed, study ongoing
- Final enrollment: 120 participants (planned 100)
- Study completion pushed from Feb 2026 to Oct 2026
- Start date: Apr 3, 2025 to Apr 10, 2025
- Site details revised
- Publications: details revised at 2 of 2 entries
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Mar 2025 to Apr 3, 2025
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
The all-cause mortality rate at Day 14.
Timeframe: From the first dose of the study drug to Day 14.
Secondary (6)
The all-cause mortality rate at Day 28.
The total ventilation time.
The percentage of participants with microbiologic eradication at the early assessment (EA) period.
The percentage of participants with microbiologic eradication at the end of treatment (EOT) period.
The percentage of participants with microbiologic eradication at the test of cure (TOC) period.
Show 1 moreShow less
The percentage of participants with microbiologic eradication at the follow-up (FU) period.
Arms and interventions
HRS-8427Experimental
MeropenemActive comparator
Drugs: HRS-8427, Meropenem
Sites
1 site in 1 country
- China-Japan Friendship HospitalBeijing, Beijing Municipality, China